经导管主动脉瓣血栓形成:发生率、易感因素与临床意义
本研究纳入460例连续接受Edwards Sapien XT或Sapien 3经导管心脏瓣膜(THV)行经导管主动脉瓣置换术(TAVR)的患者,其中405例(88%)在术后1至3个月接受对比增强多排CT(MDCT)检查。MDCT证实28例(7%)存在THV血栓形成,未使用华法林者风险更高(10.7% vs 1.8%;RR:6.09;95%CI:1.86至19.84),29 mm瓣膜与未使用华法林为独立预测因素,华法林治疗使85%患者血栓逆转并恢复正常瓣膜功能。
要点
- TAVR术后1至3个月MDCT证实的THV血栓发生率为7%,多为亚临床。
- 未使用华法林者THV血栓风险显著升高(RR:6.09;95%CI:1.86至19.84)。
- 29 mm瓣膜与未使用华法林为独立预测因素,华法林可使85%患者血栓逆转。
核心结论
- TAVR术后THV血栓发生率为7%,较大尺寸瓣膜可能易化血栓形成,而华法林治疗似有保护作用。
- THV血栓虽常为亚临床,但可能具有重要临床意义。
研究设计与样本
- 研究为单中心连续病例系列,460例接受Edwards Sapien XT或Sapien 3 THV行TAVR的患者中405例(88%)于术后1至3个月接受MDCT及经胸、经食管超声心动图检查。
- MDCT以低衰减瓣叶增厚判定THV血栓。
主要发现
- 405例中28例(7%)经MDCT证实THV血栓,其中23例为亚临床血栓,5例(18%)出现临床显性梗阻性THV血栓。
- 不同代际THV之间血栓风险无差异(8% vs 6%;p=0.42)。
- 未使用华法林者THV血栓风险高于使用华法林者(10.7% vs 1.8%;RR:6.09;95%CI:1.86至19.84)。
- 较大尺寸THV与THV血栓风险增加相关(p=0.03);多变量分析中29 mm THV(RR:2.89;95%CI:1.44至5.80)与TAVR术后未使用华法林(RR:5.46;95%CI:1.68至17.7)为独立预测因素。
关键数值与推荐
- THV血栓发生率:28/405(7%)。
- 临床显性梗阻性THV血栓:5/28(18%)。
- 未使用华法林者THV血栓风险RR:6.09(95%CI:1.86至19.84)。
- 多变量独立预测因素:29 mm THV(RR:2.89;95%CI:1.44至5.80)、术后未使用华法林(RR:5.46;95%CI:1.68至17.7)。
- 华法林治疗使85%患者THV血栓逆转并经随访经食管超声与MDCT证实瓣膜功能恢复正常。
临床怎么用
- TAVR术后1至3个月可考虑MDCT筛查THV血栓,尤其是使用较大尺寸瓣膜或未接受华法林抗凝的患者。
- 对发现的THV血栓,华法林治疗可有效逆转血栓并恢复瓣膜功能。
局限性
- 研究为单中心连续病例系列,405/460例(88%)接受MDCT,未接受MDCT者情况未报告。
- 原文未报告随机对照设计、盲法评估及长期随访结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on the incidence, clinical implications, and predisposing factors of transcatheter heart valve (THV) thrombosis following transcatheter aortic valve replacement (TAVR). OBJECTIVES: The authors assessed the incidence, potential predictors, and clinical implications of THV thrombosis as determined by contrast-enhanced multidetector computed tomography (MDCT) after TAVR. METHODS: Among 460 consecutive patients who underwent TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) THV, 405 (88%) underwent MDCT in addition to transthoracic and transesophageal echocardiography 1 to 3 months post-TAVR. MDCT scans were evaluated for hypoattenuated leaflet thickening that indicated THV thrombosis. RESULTS: MDCT verified THV thrombosis in 28 of 405 (7%) patients. A total of 23 patients had subclinical THV thrombosis, whereas 5 (18%) patients experienced clinically overt obstructive THV thrombosis. THV thrombosis risk did not differ among different generations of THVs (8% vs. 6%; p = 0.42). The risk of THV thrombosis in patients who did not receive warfarin was higher compared with patients who received warfarin (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.86 to 19.84). A larger THV was associated with an increased risk of THV thrombosis (p = 0.03). In multivariable analysis, a 29-mm THV (RR: 2.89; 95% CI: 1.44 to 5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68 to 17.7) independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of patients as documented by follow-up transesophageal echocardiography and MDCT. CONCLUSIONS: Incidence of THV thrombosis in this large study was 7%. A larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective effect. Although often subclinical, THV thrombosis may have important clinical implications.
引用
- Hansson NC, Grove EL, Andersen HR, et al. Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications. J Am Coll Cardiol. 2016. PMID: 27580689. doi:10.1016/j.jacc.2016.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。